company background image
2186 logo

Luye Pharma Group SZSC:2186 Stock Report

Last Price

HK$2.02

Market Cap

HK$7.6b

7D

0%

1Y

-32.2%

Updated

07 May, 2025

Data

Company Financials +

2186 Stock Overview

Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. More details

2186 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 2186 from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Luye Pharma Group Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Luye Pharma Group
Historical stock prices
Current Share PriceHK$2.02
52 Week HighHK$3.75
52 Week LowHK$1.67
Beta0.79
1 Month Change9.78%
3 Month Change-4.72%
1 Year Change-32.21%
3 Year Change-13.30%
5 Year Change-48.86%
Change since IPO-59.68%

Recent News & Updates

Recent updates

Shareholder Returns

2186HK PharmaceuticalsHK Market
7D0%-0.7%2.0%
1Y-32.2%9.8%15.5%

Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned 10.5% over the past year.

Return vs Market: 2186 underperformed the Hong Kong Market which returned 14.5% over the past year.

Price Volatility

Is 2186's price volatile compared to industry and market?
2186 volatility
2186 Average Weekly Movement7.6%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement8.1%
10% most volatile stocks in HK Market15.5%
10% least volatile stocks in HK Market4.3%

Stable Share Price: 2186 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2186's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19945,150Dian Bo Liuwww.luye.cn

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine.

Luye Pharma Group Ltd. Fundamentals Summary

How do Luye Pharma Group's earnings and revenue compare to its market cap?
2186 fundamental statistics
Market capHK$7.60b
Earnings (TTM)HK$506.84m
Revenue (TTM)HK$6.51b

15.0x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2186 income statement (TTM)
RevenueCN¥6.06b
Cost of RevenueCN¥2.02b
Gross ProfitCN¥4.04b
Other ExpensesCN¥3.57b
EarningsCN¥471.89m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin66.72%
Net Profit Margin7.79%
Debt/Equity Ratio65.1%

How did 2186 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 02:55
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Luye Pharma Group Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Jessica LiBofA Global Research
Lok Kwan ChiuCCB International Securities Limited